Photo from wikipedia
The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative… Click to show full abstract
The JAK/STAT inhibitor tofacitinib, recently approved for the treatment of ulcerative colitis, is found to modulate the intestinal endothelial barrier functions in directing the leukocyte adhesion and transmigration in ulcerative colitis patients displaying high levels of endothelial STAT3/STAT6 phosphorylation.
Keywords:
intestinal endothelial;
endothelial barrier;
colitis patients;
colitis;
ulcerative colitis
Journal Title: Inflammatory bowel diseases
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Inflammatory bowel diseases
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!